Clear answers for patients, physicians and professional partners.

CELLMEX is a regenerative medicine and biotechnology platform focused on cellular therapies, cell-free biological technologies, laboratory research and physician-led clinical evaluation.

The platform includes mesenchymal stromal cells, extracellular-vesicle technologies, secretome-associated preparations, conditioned media, tissue-directed cellular research and selected immune-cell technologies.

No. CELLMEX is being developed as a broader regenerative medicine platform integrating laboratory work, scientific review, clinical evaluation, physician collaboration and cell-free as well as cellular technologies.

The current technology portfolio includes:

• Mesenchymal stromal-cell platforms
• Purified or enriched exosome preparations
• Small extracellular vesicles
• MSC secretome
• Conditioned media
• Exosome-depleted conditioned media
• Tissue-directed or differentiated MSC research
• Selected immune-cell technologies

No. They are scientifically distinct.

Stem- or stromal-cell products contain living cells. Extracellular vesicles are membrane-bound particles released by cells. Secretome refers broadly to the mixture of soluble and vesicular materials released by cells. Conditioned media is culture medium collected after exposure to cells and may contain a mixture of those secreted components.

No. Biological responses vary between patients, and no responsible clinical provider should guarantee a cure, permanent improvement or a specific result.

Expected benefits, uncertainties, alternatives, limitations and possible risks should be discussed before treatment.

No. In-vitro and ex-vivo research may help explain biological activity or support a scientific rationale, but laboratory findings do not automatically establish safety or clinical effectiveness in people.

Eligibility requires individual medical review. The clinical team may consider:

• Confirmed diagnosis
• Disease severity and duration
• Previous and current treatments
• Current medication
• Medical history and comorbidities
• Laboratory and imaging results
• Potential contraindications

Submission of an enquiry does not guarantee acceptance for treatment.

A confirmed diagnosis is generally required. Regenerative treatment should not be used as a substitute for proper diagnostic investigation.

Additional testing or specialist evaluation may be requested if the diagnosis is incomplete or uncertain.

Patients are normally asked to provide:

• Physician or specialist reports
• Laboratory test results
• Imaging reports and relevant images
• Surgical or hospital records
• Pathology reports, where applicable
• Current medication and allergy information
• A summary of previous treatment

Treatment cost depends on the diagnosis, proposed biological platform, number of applications, route of administration, required testing, physician services and follow-up.

After medical evaluation, eligible patients should receive a written treatment plan and cost estimate before making a commitment.

This depends on the final CELLMEX fee structure. The patient coordinator should confirm whether record review, consultation, laboratory studies and treatment are quoted separately or together.

Website administrator: Replace this answer after CELLMEX approves its final consultation and treatment-fee policy.

Not necessarily. Some patients require physical examination, laboratory testing, imaging, specialist clearance or additional medical review before treatment can be scheduled.

No medication should be stopped or changed unless instructed by a qualified physician. Abrupt medication changes may create serious medical risks.

Preparation depends on the procedure. Instructions may address:

• Eating and drinking
• Medication management
• Recent infection or fever
• Transportation after treatment
• Laboratory testing
• Clothing and mobility requirements

Follow only the instructions issued for your individual treatment.

Follow-up may include physician review, symptom monitoring, laboratory tests, imaging, adverse-event assessment and communication with the patient's regular physician.

It should not automatically replace proven standard care. Regenerative interventions should be evaluated alongside established treatment options and coordinated with the patient's physicians when appropriate.

Travel suitability depends on the patient's medical stability, mobility, diagnosis, recent procedures and proposed treatment.

Certain patients may require medical clearance from their regular physician before flying or undertaking prolonged travel.

No. International patients should wait until medical records have been reviewed and CELLMEX has confirmed acceptance, proposed dates and anticipated length of stay.

The required stay depends on the treatment, number of appointments, preliminary testing and need for post-treatment observation.

Some patients may require several days; others may need a longer stay. The anticipated schedule should be confirmed in writing before travel.

The international patient team may assist with recommended arrival dates, appointment scheduling, information concerning nearby accommodation, and local transportation guidance.

Patients remain responsible for passports, visas, airline tickets, hotel contracts, insurance and personal expenses unless a service is expressly included in writing.

Entry requirements depend on nationality, travel documents, country of residence and current Mexican immigration rules.

Patients should verify requirements with the appropriate Mexican consular or immigration authority before travel. CELLMEX should not provide legal or immigration guarantees.

A companion may be recommended for patients with reduced mobility, complex medical conditions, language needs, sedation-related procedures or those requiring assistance after treatment.

Travel, accommodation, meals and personal expenses should be treated as separate unless specifically included in the written quotation.

Records in English or Spanish are generally the most practical for review. Documents in another language may require a reliable medical translation.

With the patient's written authorisation, CELLMEX may communicate relevant clinical information to the patient's regular physician or specialist.

Follow-up may include remote consultations, symptom review, laboratory or imaging recommendations and communication with the patient's local physician.

Patients should receive written discharge and follow-up instructions before departure.

Mesenchymal stromal cells, commonly called MSCs, are culture-expanded stromal-cell populations that may be obtained from sources such as bone marrow, adipose tissue and umbilical-cord tissue.

Their proposed biological activity includes immunomodulatory and paracrine signalling, rather than simply replacing damaged tissue through direct differentiation.

Exosomes are a subtype of small extracellular vesicle associated with the endosomal cellular pathway. They may carry proteins, lipids and nucleic acids.

A preparation should not be called purified exosomes solely because particles fall within a particular size range. Manufacturing, separation and characterisation data are required.

Small extracellular vesicles are membrane-bound particles released by cells. They may include mixed vesicle populations, and their precise biogenesis may not always be established.

The MSC secretome is the broad collection of soluble and vesicular components released by MSCs under defined culture conditions.

It may contain cytokines, chemokines, growth factors, metabolites, proteins, nucleic acids and extracellular vesicles.

Conditioned media is cell-culture medium collected after it has been exposed to living cells. Its composition depends on the cell source, culture conditions, collection time and processing method.

It is conditioned media processed to reduce or remove selected extracellular-vesicle fractions while retaining soluble cell-secreted components.

The degree of vesicle depletion should be analytically demonstrated rather than assumed.

Differentiated or tissue-directed MSCs are MSC populations exposed to controlled culture conditions intended to influence lineage-associated characteristics or phenotype.

Claims of differentiation should be supported by appropriate identity, phenotype and functional testing.

Immune-cell therapies involve selected immune populations that may be isolated, activated, expanded or modified for a defined purpose.

Different immune-cell therapies have very different evidence, manufacturing, regulatory and safety profiles.

Many exosome, extracellular-vesicle and secretome applications remain investigational. Laboratory and preclinical research may be substantial, but clinical evidence, product standardisation and regulatory status vary.

A proposed application should be evaluated individually rather than described as generally proven.

Risks depend on the product, source, manufacturing process, route of administration and patient condition. They may include:

• Infection or contamination
• Immune or inflammatory reactions
• Procedure-related complications
• Thrombotic or vascular complications
• Local pain, swelling or tissue injury
• Product inconsistency
• Lack of clinical benefit
• Unanticipated biological effects

The relevant risks should be explained in the patient-specific informed-consent process.

The referring physician should submit a clinical summary including the diagnosis, disease status, current medication, previous treatment, relevant laboratory or imaging findings and reason for referral.

Use the Medical Affairs section on the physician portal .

Eligibility is determined through physician-led medical review. CELLMEX may consult with the referring physician and request additional testing or specialist clearance.

Yes. Protocol availability depends on the technology, intended use, jurisdiction and professional credentials of the requester.

Protocols may include patient-selection, preparation, administration, monitoring, follow-up and adverse-event considerations.

A protocol may require medically justified adaptation based on diagnosis, severity, comorbidities, medication, previous treatment and clinical risk.

Customisation should not bypass quality, safety, scientific or regulatory requirements.

Yes. Physicians may request peer-reviewed literature, evidence summaries, technical reports and available CELLMEX white papers.

The Medical Publications Library provides selected literature with author, journal, DOI and PubMed information.

Where medically appropriate, CELLMEX may evaluate how a regenerative intervention could be coordinated with the patient's standard care and specialist treatment.

Physicians should submit a professional enquiry identifying:

• Technology or product requested
• Intended clinical or research use
• Destination and jurisdiction
• Required quantity
• Desired treatment date
• Storage and shipping capabilities
• Physician and facility credentials

Depending on the product and programme, available documentation may include:

• Product description
• Biological source information
• Handling and storage instructions
• Available quality documentation
• Administration guidance
• Clinical references
• Patient eligibility guidance
• Follow-up templates

CELLMEX may support international medical enquiries, patient referrals, scientific discussions and treatment coordination, subject to professional, import, supply and regulatory considerations.

Yes. Use the physician portal to request clinical consultation, protocol review, scientific literature, laboratory consultation, ordering information or research collaboration.

Yes. Potential collaboration may include patient referrals, physician education, clinical-programme design, laboratory services, research cooperation or access to defined biological platforms.

The structure depends on the institution, jurisdiction, medical specialty, professional capabilities and applicable regulation.

Supply is not automatic. CELLMEX may first review the institution's licences, physicians, facilities, storage, administration capabilities, intended use and applicable legal requirements.

CELLMEX may discuss programme development, including:

• Clinical scope
• Physician responsibilities
• Patient-selection criteria
• Treatment workflow
• Storage and handling
• Informed consent
• Follow-up and adverse-event reporting
• Laboratory and supply coordination

Training may be considered for approved professional partners. It may cover product handling, patient selection, treatment workflow, clinical documentation and follow-up.

Training does not replace professional licensing, specialty competence or institutional credentialing.

An institutional enquiry should include:

• Legal name and location
• Facility type
• Medical specialties
• Responsible physicians
• Licences or registrations
• Proposed patient population
• Technology of interest
• Expected treatment volume
• Storage and administration capabilities

Available technical and quality information may be shared following professional verification, confidentiality review and identification of the precise product or programme involved.

Territorial rights should not be assumed. Any exclusivity, distribution, representation or clinical partnership would require written commercial and legal agreement.

Current areas may include:

• MSC culture and expansion conditions
• Cellular morphology and behaviour
• Secreted soluble and vesicular components
• Conditioned-media processing
• Extracellular-vesicle separation and characterisation
• Cryogenic preservation
• Tissue-directed cellular research
• In-vitro and ex-vivo biological applications

Yes. A proposal should define the research question, biological material, methods, expected outputs, responsibilities, intellectual-property considerations, funding and required ethical or regulatory review.

Research-sample availability depends on the material, intended use, institution, transfer conditions, documentation and legal or ethical requirements.

No sample should be assumed available without an approved written request and material-transfer terms.

Joint publication may be considered where CELLMEX personnel make a genuine scientific contribution. Authorship should follow accepted academic criteria and be agreed transparently.

CELLMEX research should use appropriate EV nomenclature and characterisation standards, with MISEV2023 serving as an important scientific reference for study design and reporting.

Data access depends on the project, confidentiality terms, ownership, publication strategy, patient or donor privacy and the relevant collaboration agreement.

Not automatically. In-vitro and ex-vivo laboratory studies are different from interventional clinical trials involving human participants.

A clinical trial requires its own protocol, ethical oversight, participant protection, regulatory analysis, documentation and monitoring.

Yes. Potential cooperation may include analytical testing, method development, characterisation, research studies, process comparison or specialised services.

The collaboration should clearly define scope, sample identity, chain of custody, methods, reporting, confidentiality and data ownership.

Depending on the product and purpose, relevant information may include:

• Cell source
• Donor qualification
• Passage number
• Viability
• Cell count
• Identity markers
• Sterility-related testing
• Mycoplasma testing
• Endotoxin testing
• Available functional or potency information

Availability must be confirmed for the specific preparation.

Relevant information may include:

• Source-cell type
• Culture conditions
• Isolation and purification method
• Particle concentration and size distribution
• Morphology
• EV-associated protein markers
• Assessment of non-vesicular contaminants
• Sterility-related information
• Functional or potency testing

Storage and transport requirements depend on the specific cells, formulation, presentation, stability data and intended use.

Instructions may include refrigerated, frozen, cryogenic or other controlled conditions. The applicable product-specific instructions must take precedence over general assumptions.

No such claim should be made unless it is supported by formal documentation. Development methods, research assays, qualified methods and validated methods are not equivalent.

Independent or confirmatory testing may be considered when technically appropriate and supported by agreed sample handling, shipping, chain-of-custody and testing procedures.

Requirements may include:

• Defined material identity
• Intended use
• Recipient institution information
• Shipping and storage conditions
• Import or export documentation
• Material-transfer agreement
• Confidentiality terms
• Ethical or regulatory authorisation

Treatments should be performed only at the facility identified in the patient's written appointment and treatment documentation.

The exact location may depend on the procedure, physician, required equipment and patient needs.

Laboratory processing and clinical treatment are separate functions. A laboratory is not automatically an appropriate treatment room or clinical facility.

Administration should occur in a clinical environment suitable for the proposed procedure and required monitoring.

Laboratory access may be restricted for safety, contamination control, confidentiality and operational reasons. Professional visits require advance approval.

Availability depends on the physician, clinical programme, treatment type, required equipment and approved facility. Patients should not assume that every procedure is available at every location.

Verify the facility name, complete address, date, time, physician and patient coordinator using CELLMEX's confirmed written communication before travelling.

Do not rely solely on an address provided through an unofficial social-media account, intermediary or third party.

Some services may potentially involve affiliated physicians or approved clinical facilities. Any such involvement should be disclosed to the patient or professional partner before treatment or contracting.

No. An online enquiry is an initial communication and does not itself establish a diagnosis, treatment recommendation, confirmed eligibility or physician-patient relationship.

A general website form should collect only the minimum information needed to begin an enquiry.

Detailed medical records should be transferred through the secure method specified by the patient-coordination or Medical Affairs team.

Informed consent is a process through which the patient receives an understandable explanation of the proposed treatment, alternatives, uncertainties, potential benefits, possible risks, follow-up requirements and the right to decline.

Signing a document alone is not a substitute for an adequate discussion.

Patients should follow the emergency and adverse-event instructions issued by the treating team. Serious or unexpected symptoms require prompt medical assessment.

Physicians and institutions should document and report events through the applicable clinical, pharmacovigilance or regulatory channels.

CELLMEX should establish a formal review cycle for this page. Scientific, clinical, operational and regulatory information should be reviewed whenever material changes occur and at least periodically by responsible medical, scientific and legal personnel.